{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T07:03:10Z","timestamp":1724569390860},"reference-count":81,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.bulcan.2016.06.006","type":"journal-article","created":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T22:32:49Z","timestamp":1470522769000},"page":"880-895","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prise en charge th\u00e9rapeutique des tumeurs neuroendocrines peu diff\u00e9renci\u00e9es pulmonaires et des carcinomes neuroendocrines digestifs"],"prefix":"10.1016","volume":"103","author":[{"given":"Anna","family":"Pellat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Svrcek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Hammel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Afchain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2016.06.006_bib0410","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825\u00a0cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0415","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.ejca.2012.12.022","article-title":"Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry","volume":"49","author":"Korse","year":"2013","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2016.06.006_bib0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.revmed.2016.01.012","article-title":"[Digestive neuroendocrine tumors]","volume":"37","author":"De Mestier","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0425","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30\u00a0years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2016.01.003","article-title":"Large-cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes","author":"Naidoo","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0435","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cllc.2012.07.002","article-title":"Combined SCLC clinical and pathologic characteristics","volume":"14","author":"Babakoohi","year":"2013","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2016.06.006_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.annpat.2015.11.008","article-title":"[Pulmonary neuroendocrine tumors and preneoplasic lesions]","volume":"36","author":"Rouquette Lassalle","year":"2016","journal-title":"Ann Pathol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0445","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/cncr.20043","article-title":"Neurologic disorders in 432\u00a0consecutive patients with small-cell lung carcinoma","volume":"100","author":"Seute","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0450","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015\u00a0World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004\u00a0classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0455","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.lungcan.2013.05.008","article-title":"High-grade neuroendocrine lung tumors: pathological characteristics, surgical management and prognostic implications","volume":"81","author":"Grand","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0460","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ecl.2010.08.009","article-title":"Pathology of gastrointestinal disorders","volume":"39","author":"Rindi","year":"2010","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0810","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2015-0476","article-title":"Gastroenteropancreatic well-differentiated grade 3\u00a0neuroendocrine tumors: review and position statement","author":"Coriat","year":"2016","journal-title":"Oncologist"},{"issue":"4\u00a0suppl","key":"10.1016\/j.bulcan.2016.06.006_bib0815","first-page":"518","article-title":"Epidemiology and survival of small-cell carcinoma of gastrointestinal tract: a Surveillance, Epidemiology and End Results (SEER) database review","volume":"34","author":"Srinath Sundararajan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0475","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0480","series-title":"Th\u00e9saurus national de canc\u00e9rologie digestive","author":"Soci\u00e9t\u00e9 nationale fran\u00e7aise de gastro-ent\u00e9rologie","year":"2016"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0485","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305\u00a0patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0490","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.annpat.2014.01.003","article-title":"[Gastroenteropancreatic neuroendocrine tumors: what must the pathologist know and do in 2014?]","volume":"34","author":"Scoazec","year":"2014","journal-title":"Ann Pathol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0495","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/cncr.22887","article-title":"Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study","volume":"110","author":"Cicin","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0500","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.109.069765","article-title":"Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET","volume":"51","author":"Binderup","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0505","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1245\/s10434-014-3725-3","article-title":"A retrospective review of 126\u00a0high-grade neuroendocrine carcinomas of the colon and rectum","volume":"21","author":"Smith","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0510","doi-asserted-by":"crossref","first-page":"320S","DOI":"10.1378\/chest.106.6_Supplement.320S","article-title":"A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small-cell lung cancer to combination chemotherapy","volume":"106","author":"Lad","year":"1994","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.bulcan.2016.06.006_bib0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.athoracsur.2015.12.009","article-title":"A single institution analysis of the surgical management of pulmonary large-cell neuroendocrine carcinomas","volume":"101","author":"Roesel","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0520","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1200\/JCO.2002.12.111","article-title":"Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5\u00a0years\u2019 follow-up","volume":"20","author":"Sundstrom","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0525","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.2000.18.2.395","volume":"18","author":"Thatcher","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0530","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0535","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","article-title":"A meta-analysis of thoracic radiotherapy for small-cell lung cancer","volume":"327","author":"Pignon","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0540","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2004.06.070","article-title":"Phase II trial of cisplatin\/etoposide and concurrent radiotherapy followed by paclitaxel\/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713","volume":"22","author":"Edelman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0545","article-title":"[Small-cell lung cancer (CPC). Management of patients presenting with limited stage small-cell carcinoma of the lung]","volume":"23","author":"Le Pechoux","year":"2006","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0550","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104","volume":"20","author":"Takada","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0820","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.1997.15.3.893","article-title":"Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study","volume":"15","author":"Jeremic","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0560","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0565","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1200\/JCO.1999.17.9.2681","article-title":"Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma","volume":"17","author":"Bonner","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0570","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40001-015-0158-9","article-title":"Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas","volume":"20","author":"Rieber","year":"2015","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0575","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11864-015-0372-2","article-title":"The role of radiotherapy in the treatment of small-cell lung cancer","volume":"16","author":"Nosaki","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0580","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","article-title":"Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group","volume":"10","author":"Roth","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0585","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/93.4.300","article-title":"Etoposide plus cisplatin with or without the combination of 4\u2019-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study","volume":"93","author":"Pujol","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0590","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0595","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124","volume":"27","author":"Lara","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0600","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2005.09.071","article-title":"Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732","volume":"23","author":"Niell","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0605","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","article-title":"Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer","volume":"27","author":"Socinski","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2016.06.006_bib0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14656566.2016.1154539","article-title":"Optimal drugs for second-line treatment of patients with small-cell lung cancer","volume":"17","author":"Rossi","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0615","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0620","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","article-title":"Phase II trial of temozolomide in patients with relapsed sensitive or refractory small-cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker","volume":"18","author":"Pietanza","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0625","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.1985.3.1.65","article-title":"Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer","volume":"3","author":"Evans","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0630","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cllc.2013.11.003","article-title":"Third-line chemotherapy in small-cell lung cancer: an international analysis","volume":"15","author":"Simos","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0635","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"O\u2019Brien","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0640","doi-asserted-by":"crossref","first-page":"e73805","DOI":"10.1371\/journal.pone.0073805","article-title":"Duration of chemotherapy for small-cell lung cancer: a meta-analysis","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0645","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive-stage small-cell lung cancer: a phase 3\u00a0randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0650","first-page":"533","article-title":"Novel therapies in small-cell lung cancer","volume":"4","author":"Mamdani","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0655","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2\u00a0trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0660","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.7503","article-title":"Phase I\/II study of nivolumab with or without ipilimumab for treatment of recurrent small-cell lung cancer (SCLC): CA209-032","volume":"33","author":"Antonia","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0665","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/DCR.0000000000000298","article-title":"Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis","volume":"58","author":"Shafqat","year":"2015","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0670","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/annonc\/mdm476","article-title":"Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience","volume":"19","author":"Ku","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0675","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1366::AID-CNCR2>3.0.CO;2-D","article-title":"Primary small-cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis","volume":"80","author":"Casas","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0680","doi-asserted-by":"crossref","first-page":"e1864","DOI":"10.1097\/MD.0000000000001864","article-title":"Radiochemotherapy versus surgery in nonmetastatic anorectal neuroendocrine carcinoma: a multicenter study by the Association des Gastro-Ent\u00e9rologues Oncologues","volume":"94","author":"Brieau","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0685","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0690","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1200\/JCO.2005.05.0575","article-title":"Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study","volume":"24","author":"Hainsworth","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0695","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jjco\/hys085","article-title":"Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas","volume":"42","author":"Nakano","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0700","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0705","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-006-0306-6","article-title":"Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?","volume":"59","author":"Bajetta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0710","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/ERC-12-0002","article-title":"FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3","volume":"19","author":"Hentic","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0715","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3\u00a0neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2016.06.006_bib0720","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1994.12.10.2022","article-title":"Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer","volume":"12","author":"Ihde","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0725","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0730","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/thx.2007.093872","article-title":"Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small-cell lung cancer","volume":"64","author":"Lee","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0735","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2013.53.5153","article-title":"Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509","volume":"32","author":"Satouchi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0740","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0745","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0169-5002(03)00273-3","article-title":"Phase II study of second-line gemcitabine in sensitive or refractory small-cell lung cancer","volume":"42","author":"Hoang","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0750","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lungcan.2003.10.003","article-title":"Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small-cell lung cancer","volume":"44","author":"Ando","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0755","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00280-005-0114-4","article-title":"Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer","volume":"58","author":"Mori","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0760","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00280-005-0157-6","article-title":"Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial","volume":"58","author":"Dongiovanni","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0765","first-page":"777","article-title":"Phase II study of weekly paclitaxel for relapsed and refractory small-cell lung cancer","volume":"26","author":"Yamamoto","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0770","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-007-0496-6","article-title":"Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer","volume":"61","author":"Ohyanagi","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0775","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cncr.24753","article-title":"Phase 2\u00a0study of irinotecan and paclitaxel in patients with recurrent or refractory small-cell lung cancer","volume":"116","author":"Ramalingam","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0780","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0785","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jjco\/hyp173","article-title":"Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas","volume":"40","author":"Iwasa","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0790","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.4081\/rt.2013.e39","article-title":"Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas","volume":"5","author":"Ramella Munhoz","year":"2013","journal-title":"Rare Tumors"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0795","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/cas.12473","article-title":"Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system","volume":"105","author":"Yamaguchi","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0800","first-page":"5037","article-title":"Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus","volume":"34","author":"Okuma","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0805","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.26124","article-title":"Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy","volume":"117","author":"Welin","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2016.06.006_bib0405","doi-asserted-by":"crossref","first-page":"170496","DOI":"10.1100\/2012\/170496","article-title":"Temozolomide as second- or third-line treatment of patients with neuroendocrine carcinomas","volume":"2012","author":"Olsen","year":"2012","journal-title":"Sci World J"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116301059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116301059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T20:11:19Z","timestamp":1699042279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455116301059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":81,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0007455116301059"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.06.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge th\u00e9rapeutique des tumeurs neuroendocrines peu diff\u00e9renci\u00e9es pulmonaires et des carcinomes neuroendocrines digestifs","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}